A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis
Top Cited Papers
- 1 December 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 123 (6), 1037-1044
- https://doi.org/10.1111/j.0022-202x.2004.23448.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-αThe Journal of Experimental Medicine, 2004
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: Case report and review of the literatureAmerican Journal of Hematology, 2002
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Expression of Interleukin-12 is Increased in Psoriatic SkinJournal of Investigative Dermatology, 1998
- Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reactionJournal of Dermatological Science, 1991
- Psoriasis and bone marrow transplantation.BMJ, 1990
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978